Diluted EPS came in at $-0.12 (+14.3% YoY).
Trailing eight quarters through Q1 2026
Common questions about Ovid Therapeutics's Q1 2026 earnings report.
Ovid Therapeutics (OVID) reported Q1 2026 earnings on May 12, 2026 before market open.
Ovid Therapeutics reported diluted EPS of $-0.12 for Q1 2026.
EPS beat the consensus estimate of $-0.12 by $0.00.
Compared to the same quarter a year prior, diluted EPS grew 14.3% from $-0.14.
You can read the 8-K earnings release (0001628280-26-033859) and the 10-Q periodic report (0001628280-26-033864) directly on SEC EDGAR. The filing index links above go to sec.gov.